IRPA9

1996 International Congress on Radiation Protection April 14-19,1996 Vienna, Austria

FORM FOR SUBMISSION OF ABSTRACTS (Instructions for preparation on reverse)

organ contents are given.

PAPER TITLE

FOR OFFICIAL USE ONLY
Abstract No.
Receipt
Author
Acceptance
Mini-Presentation

in humans for use in internal
· · · · · · · · · · · · · · · · · · ·
Ontario, Canada
ME John TITLEChief Scientist
TEL_(509)_375-6850
FAX (509) 375-2019
COUNTRY USA
lied and is well known. Despite
ke, distribution, and retention
ernal dosimetry. Carbon-14 is
O ₂ , and in nuclear medicine and Environmental ¹⁴ C will become
14Chwill_existmas.anlinsoluble
take from these different ationship between intake and

excretion. This paper describes a physiologically based pharmacokinetic (PBPK) model

that has been developed for use with bioassay to evaluate the dose from an intake of ¹⁴C. The model has been used to calculate committed effective and equivalent dose following inhalation intakes of compounds containing ¹⁴C as gases and vapors, and as Type F, M, and S compounds, as well as from ingestion intakes. Data useful in relating measurable quantities (chest contents, and urine and fecal excretion) to

- 1. Submitting and presenting author, Health Protection Department, PNL
- Ontario Hydro Health Physics Department, Whitby, Ontario, Canada